Sanofi's Adjuvant Produces a High Immune Response at Low Dose
Sanofi Pasteur (Lyon, France) has produced data showing that its new investigational H5N1 pandemic influenza vaccine containing a proprietary adjuvant achieved a high immune response at the lowest dose of H5N1 antigen reported to date.
Sanofi Pasteur (Lyon, France) has produced data showing that its new investigational H5N1 pandemic influenza vaccine containing a proprietary adjuvant achieved a high immune response at the lowest dose of H5N1 antigen reported to date.
The vaccine containing 1.9 micrograms of antigen generated a high level of seroprotective immune response in over 70% of the participants in a clinical trial and, in the same clinical trial, vaccine containing 3.75 micrograms of antigen generated a high level of seroprotective immune response in over 80% of the participants. Further assessment of the vaccine is ongoing.
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
